

Product datasheet for **TA306428**

p16INK4A (CDKN2A) Rabbit Polyclonal Antibody

Product data:

Product Type:	Primary Antibodies
Applications:	ELISA, IF, IHC, WB
Recommended Dilution:	WB: 1 - 4 µg/mL; IHC-P: 5 - 10 µg/mL; IF: 20 µg/mL. Antibody validated: Western Blot in human and mouse samples; Immunohistochemistry in human and rat samples; Immunofluorescence in human and rat samples. All other applications and species not yet tested.
Reactivity:	Human, Mouse, Rat
Host:	Rabbit
Isotype:	IgG
Clonality:	Polyclonal
Immunogen:	CDKN2A antibody was raised against a 18 amino acid peptide from near the amino terminus of human CDKN2A.
Formulation:	PBS containing 0.02% sodium azide.
Purification:	CDKN2A Antibody is affinity chromatography purified via peptide column.
Conjugation:	Unconjugated
Storage:	Store at -20°C as received.
Stability:	Stable for 12 months from date of receipt.
Gene Name:	cyclin-dependent kinase inhibitor 2A
Database Link:	NP_000068 Entrez Gene 12578 Mouse Entrez Gene 25163 Rat Entrez Gene 1029 Human P42771



[View online »](#)

Background:	The CDKN2A locus gives rise to 2 distinct transcripts from different promoters. The transcripts have been designated p16(INK4A) and p14(ARF). This chromosomal region undergoes a number of inversions, translocations, heterozygous deletions, and homozygous deletions in a variety of malignant cell lines including those from glioma, non-small cell lung cancer, leukemia, and melanoma. Deletion of the region containing CDKN2A is found in more than half of all melanoma cell lines. Conversely, transfection of CDKN2A suppressed the growth of two independent mesothelioma cell lines, suggesting that inactivation of the CDKN2 gene is an essential step in the etiology of malignant mesotheliomas. CDKN2A induces a G1 cell cycle arrest by inhibiting the phosphorylation of the Rb protein by the cyclin-dependent kinases CDK4 and CDK6. CDKN2A is expressed as at least three distinct isoforms.
Synonyms:	ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4
Protein Families:	Druggable Genome
Protein Pathways:	Bladder cancer, Cell cycle, Chronic myeloid leukemia, Glioma, Melanoma, Non-small cell lung cancer, p53 signaling pathway, Pancreatic cancer, Pathways in cancer